Study of Oral TP-3654 in Patients with Myelofibrosis

IRB/UVA Tracking #
22371
Principal Investigator
Firas El Chaer
Contact
Ioannis Vassalos
Contact Phone
434.924.9496
Official Trial Title
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis
Study Description

The University of Virginia Cancer Center seeks adults ages 18 or older for a research study that looks at a potential new drug for myelofibrosis. You may be eligible for this study if you have primary or secondary myelofibrosis, and the standard treatment you have taken for it has not been helpful.

Study involves a screening period followed by 28-day treatment cycles that can continue as long as you are getting benefit out of the treatment. On two of the study visit days, you will be required to stay overnight to have your heart activity continuously monitored and research blood collected.

Study-related tests and procedures and study drug will be covered by the study sponsor.

Compensation

No Compensation; Reimbursement: Up to $175 per night for hotel stay.